Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Revenue: 2010-2025

Historic Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $3.7 million.

  • Lineage Cell Therapeutics' Revenue fell 2.59% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 24.05%. This contributed to the annual value of $9.5 million for FY2024, which is 6.19% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Revenue stood at $3.7 million for Q3 2025, which was up 33.13% from $2.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Revenue high stood at $50.0 million for Q4 2021, and its period low was $391,000 during Q1 2021.
  • Its 3-year average for Revenue is $2.4 million, with a median of $2.4 million in 2023.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 13,984.51% in 2021, then crashed by 96.17% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Revenue (Quarterly) stood at $50.0 million in 2021, then slumped by 96.17% to $1.9 million in 2022, then grew by 9.03% to $2.1 million in 2023, then surged by 37.36% to $2.9 million in 2024, then fell by 2.59% to $3.7 million in 2025.
  • Its Revenue was $3.7 million in Q3 2025, compared to $2.8 million in Q2 2025 and $1.5 million in Q1 2025.